326030 — SK Biopharmaceuticals Co Share Price
0.000.00%
Last trade - 00:00- KR₩8tn
- KR₩8tn
- KR₩548bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 42.81 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -11.19% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.74 | ||
| Price to Tang. Book | 15.67 | ||
| Price to Free Cashflow | 98.81 | ||
| Price to Sales | 14.7 | ||
| EV to EBITDA | 69.78 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.04% | ||
| Return on Equity | 58.01% | ||
| Operating Margin | 17.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 25,999.03 | 418,644.53 | 246,179.12 | 354,891.56 | 547,596.28 | 720,005 | 915,740 | 34.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -37.76 | +80.47 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business.
Directors
- Jeong Wu Cho CEO (60)
- Dong Hun Lee DRC (53)
- Hae Yeong Ahn NID (64)
- Yeong Ju Bahng NID (66)
- Min Seop Song NID (51)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 1st, 2011
- Public Since
- July 2nd, 2020
- No. of Shareholders
- 144,196
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 78,313,250
- Address
- 221, SEONGNAM, 13494
- Web
- https://www.skbp.com/
- Phone
- +82 3180930114
- Auditors
- Ernst & Young Han Young
Upcoming Events for 326030
Q2 2025 SK Biopharmaceuticals Co Ltd Earnings Release
Similar to 326030
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the SK Biopharmaceuticals Co share price?
As of Today at 23:17 UTC, shares in SK Biopharmaceuticals Co are trading at KR₩102,800. This share price information is delayed by 15 minutes.
How has the SK Biopharmaceuticals Co share price performed this year?
Shares in SK Biopharmaceuticals Co last closed at KR₩102,800 and the price had moved by +23.89% over the past 365 days. In terms of relative price strength the SK Biopharmaceuticals Co share price has outperformed the FTSE Developed Asia Pacific Index by +25.3% over the past year.
What are the analyst and broker recommendations for SK Biopharmaceuticals Co?
The overall consensus recommendation for SK Biopharmaceuticals Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the SK Biopharmaceuticals Co dividend yield?
SK Biopharmaceuticals Co does not currently pay a dividend.
Does SK Biopharmaceuticals Co pay a dividend?
SK Biopharmaceuticals Co does not currently pay a dividend.
When does SK Biopharmaceuticals Co next pay dividends?
SK Biopharmaceuticals Co does not currently pay a dividend.
How do I buy SK Biopharmaceuticals Co shares?
To buy shares in SK Biopharmaceuticals Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of SK Biopharmaceuticals Co?
As of the previous close price of KR₩102,800, shares in SK Biopharmaceuticals Co had a market capitalisation of KR₩8tn.
Where are SK Biopharmaceuticals Co shares listed?
Here are the trading details for SK Biopharmaceuticals Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 326030
What kind of share is SK Biopharmaceuticals Co?
Based on an overall assessment of its quality, value and momentum SK Biopharmaceuticals Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a SK Biopharmaceuticals Co share price forecast for 2025?
The analyst consensus target price for shares in SK Biopharmaceuticals Co is KR₩138,316. That is 34.55% above the last closing price of KR₩102,800.
Analysts covering SK Biopharmaceuticals Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩1,912 for the next financial year.
Find out moreWhat is the trend in the SK Biopharmaceuticals Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SK Biopharmaceuticals Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -7.8%.
As of the last closing price of KR₩102,800, shares in SK Biopharmaceuticals Co were trading -2.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the SK Biopharmaceuticals Co PE Ratio?
The SK Biopharmaceuticals Co PE ratio based on its reported earnings over the past 12 months is 42.81. The shares last closed at KR₩102,800.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of SK Biopharmaceuticals Co?
SK Biopharmaceuticals Co's management team is headed by:
- Jeong Wu Cho - CEO
- Dong Hun Lee - DRC
- Hae Yeong Ahn - NID
- Yeong Ju Bahng - NID
- Min Seop Song - NID